Format

Send to

Choose Destination
Transplant Proc. 2016 Apr;48(3):914-7. doi: 10.1016/j.transproceed.2016.01.032.

Efficacy and Feasibility of Intensity-Modulated Radiation Therapy for Prostate Cancer in Renal Transplant Recipients.

Author information

1
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan. Electronic address: jiizuka@kc.twmu.ac.jp.
2
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
3
Department of Radiation Oncology, Tokyo Women's Medical University, Tokyo, Japan.
4
Department of Urology, Juntendo University Urayasu Hospital, Chiba, Japan.
5
Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Chiba, Japan.

Abstract

BACKGROUND:

In transplant patients with localized prostate cancer, irradiation is not proposed as often as it is in healthy adults because of the post-radiation risks, such as ureteral stenosis and gastrointestinal toxicity as the result of fragile tissue. The objective of the study was to analyze the efficacy and feasibility of intensity-modulated radiation therapy (IMRT) for prostate cancer in renal transplant recipients (RTRs).

METHODS:

Between May 2005 and December 2014, all patients who had undergone IMRT for clinically localized prostate cancer at our institution were retrospectively identified (n = 365). Of these patients, 2 had a history of renal transplantation. We reviewed all available clinical data. One patient had a functioning graft and the other had restarted hemodialysis 7 years after the transplantation.

RESULTS:

The mean time from renal transplantation to prostate cancer diagnosis was 11 years. The mean follow-up after irradiation was 43 months. The 2 patients remain free of prostate-specific antigen progression. There was no severe acute and chronic genitourinary and gastrointestinal toxicity. Renal function of the patient with a functioning graft as measured by serum creatinine was stable during and after the irradiation.

CONCLUSIONS:

IMRT is feasible and acceptable as a minimally invasive treatment in the carefully selected RTRs with localized prostate cancer. This treatment should be considered a good option for RTRs with localized prostate cancer.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center